TTR and amyloidosis: Vutrisiran and Patisiran are two FDA‐approved siRNA drugs for the treatment of hereditary transthyretin‐mediated amyloidosis (hATTR).[28] Both drugs target the TTR gene and reduce its expression, preventing the formation of amyloid deposits.